BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dolutegravir (Tivicay®, Triumeq®): New study suggests risk of birth defects in babies born to women who were treated for HIV infection

2018.05.22

Active substance: dolutegravir

The European Medicines Agency (EMA) is currently evaluating preliminary results from a study which found 4 cases of birth defects.

To the risk information full text (available in German only)

For details on the review please click on the following link to the homepage of the European Medicines Agency (EMA):

New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK